L.I. MALTSEVA¹, D.M. NIKOGOSYAN²

¹Kazan State Sedical Academy, 51 Bolshaya Krasnaya St., Kazan, Russian Federation 420015

²Republican Clinical Hospital № 2, 1а Chekhova St., Kazan, Russian Federation 420012

Maltseva L.I. — D.Med.Sc., Head of the Department of Obstetrics and Gynecology № 1, tel. (843) 236-46-41, e-mail: laramalc@mail.ru¹

Nikogosyan D.M. — physician of labour department of Republican Clinical Hospital № 2, tel. +7-905-311-29-14, e-mail: diananiko@mail.ru²

The updated data on utilization efficiency of progesterone for risk reduction of premature delivery and perinatal complications are given. Meaningful data on features of the influence of micronized progesterone and progesterone caproate-17 on reduction of the incidence of premature delivery and perinatal outcomes in women with asymptomatic severe and premature abortion clinic are discussed.Based on the evaluation of the results of randomized clinical, placebo-controlled studies was clearly demonstrated the benefit of natural progesterone, primarily its micronized form, for an effective reduction of the risk of premature delivery.

Key words: premature delivery, progesterone, outcomes, risk reduction.

 

REFERENCES

1. Behrman R.E., Butler A.S., eds. Preterm birth: Causes, consequences, and prevention. Washington, DC, The National Academies Press Publ., 2007. 772 p.

2. Ananth C.V., Joseph K.S., Oyelese Y., Demissie K., Vintzileos A.M. Trends in preterm birth and perinatal mortality among singletons: United States, 1989 through 2000. Obstetrics and Gynecology, 2005, vol. 105, no. 5, pp. 1084-1091. DOI:10.1097/01.AOG.0000158124.96300.c7.

3. Jackson R.A., Gibson K.A., Wu Y.W., Croughan M.S. Perinatal outcomes in singletons following in vitro fertilization: A meta_analysis. Obstetrics and Gynecology, 2004, vol. 103, no. 3, pp. 551-563. DOI: 10.1097/01.AOG.0000114989.84822.51.

4. Goldenberg R.L., Iams J.D., Mercer B.M., et al. The preterm prediction study: The value of new vs. standard risk factors in predicting early and all spontaneous preterm births. American Journal of Public Health, 1998, vol. 88, no. 2, pp. 233-238.

5. Makatsariya A.D., Perederyaeva E.B., Pshenichnikova T.B. Metabolic syndrome and low molecular weight heparins. ConsiliumMedicum, 2006, vol. 8, no. 6, pp. 35-41. (in Russ.).

6. DanFarineInternational and European School of Continuing Education in Perinatology, Neonatology and Reproductive Medicine. Florence PressSchool. 2013.

7. Romero R., Espinoza J., Kusanovic J., et al. The pretermparturition syndrome. BJOG: An International Journal of Obstetrics and Gynaecology, 2006, vol. 113, suppl. 3, pp. 17-42. DOI: 10.1111/j.1471-0528.2006.01120.x.

8. Romero R., Nicolaides K., Conde-Agudelo A., et al. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: A systematic review and metaanalysis of individual patient data. American Journal of Obstetrics and Gynecology, 2012, vol. 206, no. 2, pp. 124.e1-124.e19. DOI: 10.1016/j.ajog.2011.12.003.

9. Leitich H., Brunbauer M., Kaider A., et al. Cervical length and dilation of the internal as detected by vaginal ultrasonography as markers for preterm delivery: A systematic review. American Journal of Obstetrics and Gynecology, 1999, vol. 181, no. 6, pp. 1465-1472.

10. Meis P., Klebanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. New England Journal of Medicine, 2003, vol. 348, no. 24, pp. 2379-2385. DOI: 10.1056/NEJMoa035140.

11. Da Fonseca E.B., Bittar R.E., Carvalho M.H.B., Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: A randomized placebo-controlled double-blind study. American Journal of Obstetrics and Gynecology, 2003, vol. 188, no. 2, pp. 419-424. DOI: 10.1067/mob.2003.41.

12. Marc J.N.C. Keirse Progesteron administration in pregnancy may prevent preterm delivery. BJOG: An International Journal of Obstetrics and Gynaecology, 1990, vol. 97, no. 2, pp. 149-154. DOI: 10.1111/j.1471-0528.1990.tb01740.x.

13. Fonseca E.B., Celik E., Parra M., et al. Progesterone and the risk of preterm birth among women with a short cervix. New England Journal of Medicine, 2007, vol. 357, no. 5, pp. 462-469. DOI: 10.1056/NEJMoa067815

14 DeFranco E.A., O’Brien J.M., Adair C.D., et al. Vaginal progesterone is associated with a decrease in risk for early preterm birth and improved neonatal outcome in women with a short cervix: A secondary analysis from a randomized, double-blind, placebo-controlled trial. Ultrasound in Obstetrics and Gynecology, 2007, vol. 30, no. 5, pp. 697-705. DOI: 10.1002/uog.5159.

15. Vaisbuch E., Hassan S.S., Mazaki-Tovi S., et al. Patients with an asymptomatic short cervix (<or=15 mm) have a high rate of subclinical intraamniotic inflammation: Implications for patient counseling. American Journal of Obstetrics and Gynecology, 2010, vol. 202, no. 5, pp. 433.e1-433.e8. DOI: 10.1016/j.ajog.2010.02.007.

16. Dodd J.M., Flenady V., Cincotta R., Crowther C.A. Prenatal administration of progesterone for preventing preterm birth. Cochrane Database of Systematic Reviews (Online), 2006, no. 1, art. no. CD004947.

17. Northen A., Norman G., Anderson K. Follow up of children exposed in utero to 17 alpha-hydroxyprogesterone caproate compared with placebo. Obstetrics and Gynecology, 2007, vol.110, no. 4, pp. 865-872. DOI: 10.1097/01.AOG.0000281348.51499.bc.

18.Caritis S., Rouse D., Peaceman A., et al. Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: A randomized controlled trial.Obstetrics and Gynecology,2009, vol. 113, no. 2, pt. 1, pp. 285-292. DOI: 10.1097/AOG.0b013e318193c677.

19.Norman J., Mackenzie F., Owen P., et al. Progesterone for the prevention of preterm birth in twin pregnancy (STOPPIT): A randomized, double-blind, placebo-controlled study and meta-analysis. The Lancet, 2009, vol. 373, no. 9680, pp. 2034-2040. DOI: 10.1016/S0140-6736(09)60947-8.

20. Нassan S.S., Romero R., Vidyadhari D., et al. Vaginal progesterone reduces the rate of preterm birth in women with a sonographic short cervix: A multicenter, randomized, double-blind, placebo-controlled trial. Ultrasound in Obstetrics and Gynecology, 2011, vol. 38, no. 1, pp. 18-31. DOI: 10.1002/uog.9017.

21 Romero J., Rebarber A., Saltzman D.H., Schwartz R., et al The prediction of recurrent preterm birth in patients on 17-alpha-hydroxyprogesterone caproate using serial fetal fibronectin and cervical length. American Journal of Obstetrics and Gynecology, 2012, vol. 207, no. 1, pp. 51.e1-51.e5. DOI: 10.1016/j.ajog.2012.04.024.

22. Grobman W. Randomised controlled trial of progesterone treatment for preterm birth preventon in nulliparous women with cervical length less than 20 mm. American Journal of Obstetrics and Gynecology, 2012, vol. 206, suppl. no. 1, p. S367.